BlackRock Investment Management’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

BlackRock Investment Management’s Portfolio CLCD Stock Details CLCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$19K	Hold	523	–	–	﹤0.01%	3407
2016 Q3	$20K	Sell	523 -43	-8%	-$636	﹤0.01%	3376
2016 Q2	$5K	Hold	566	–	–	﹤0.01%	3876
2016 Q1	$4K	Hold	566	–	–	﹤0.01%	3887
2015 Q4	$5K	Hold	566	–	–	﹤0.01%	3892
2015 Q3	$2K	Hold	566	–	–	﹤0.01%	4102
2015 Q2	$5K	Buy	+566	New	+$4.86K	﹤0.01%	3977

Other funds holding CLCD

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock Investment Management's CLCD Position: Q4 2016 in Review

BlackRock Investment Management held its CoLucid Pharmaceuticals, Inc. (CLCD) position steady in Q4 2016 at 523 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #3407.

BlackRock Investment Management first reported a position in CLCD in Q2 2015 and has held it in 7 quarters since. The position peaked at $20K in Q3 2016. 76 funds tracked by Wall St. Rank hold CLCD as of Q4 2016.

BlackRock Investment Management held 523 shares of CoLucid Pharmaceuticals, Inc. worth $19K as of Q4 2016.
BlackRock Investment Management left its CoLucid Pharmaceuticals, Inc. share count unchanged in Q4 2016.
CoLucid Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3407 holding.
BlackRock Investment Management first reported a position in CoLucid Pharmaceuticals, Inc. in Q2 2015 and has held it in 7 quarters since.
BlackRock Investment Management's CoLucid Pharmaceuticals, Inc. position peaked at $20K in Q3 2016.
76 funds tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.